DNA — Ginkgo Bioworks Holdings, Inc.

—
NYSE · Health Care · Biotechnology · CIK 1830214 ·
Last close
$8.32
Market Cap
$448.81M
52W High
$18.22
52W Low
$5.37
ADV30
2,721,209
Next earnings
2026-11-05
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 20,156,000 18,437,000 -58,548,000 -46,710,000 990,046,000 84,535,000 569,762,000
Mar 2026 19,474,000 16,376,000 -71,374,000 -82,587,000 1,033,075,000 143,864,000 589,922,000
Dec 2025 33,396,000 26,095,000 -70,046,000 -80,751,000 1,119,696,000 167,202,000 611,106,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-164,632,000
Investing CF
$105,217,000
Financing CF
$31,116,000
CapEx
$-6,557,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.23
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-6,320,601,000
Inventory
—
Receivables
$11,485,000
ST Investments
$200,857,000
EBIT TTM
$-253,321,000
Pretax Income TTM
$-255,981,000
Interest Exp TTM
—
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$130,752,000
EBITDA
$-231,000,992
Free Cash Flow
$-88,832,496
Enterprise Value
$734,729,600
Total Cash
$285,360,992
Total Debt
$397,198,016
Shares Out
53,943,682
Trailing EPS
$-4.24
Book Value
$6.09
ROE
-58.2%
ROA
-15.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 170,155,000 -303,880,000 -312,763,000 1,119,696,000 611,106,000 508,590,000 -171,059,000
Dec 2024 227,043,000 -487,727,000 -547,029,000 1,377,449,000 661,391,000 716,058,000 -319,585,000
Dec 2023 251,455,000 -768,196,000 -892,869,000 1,665,342,000 568,190,000 1,097,152,000 -295,500,000
Dec 2022 477,706,000 -2,208,952,000 -2,104,929,000 2,539,321,000 803,044,000 1,736,277,000 -252,198,000

TTM Snapshot

Revenues TTM
$111,863,000
NetIncome TTM
$-290,803,000
OpCashFlow TTM
—
Assets (Latest)
$990,046,000
Forward EPS
$-2.90

Max Pain — expiry 2026-12-18

max pain strike: $11.00 · spot: $8.44 · call oi: 41,130 · put oi: 13,937
Expected Move to 2026-12-18: ±$1.90 (22.51%) — implied range $6.54 – $10.34 · ATM straddle on $8.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CADL Candel Therapeutics, Inc. $423.61M $5.40 —
RGNX REGENXBIO Inc. $478.73M $7.24 —
FENC FENNEC PHARMACEUTICALS INC. $479.44M $13.58 —
IRLA IRulya Therapeutics Inc. $416.85M $38.45 —
TECX Tectonic Therapeutic, Inc. $392.55M $20.08 —

News headlines (Yahoo Finance, 1h cache)

Ginkgo Bioworks Holdings Inc (DNA) Q3 2026 Earnings Call Highlights: Cost Cuts, First Big ...
2026-11-12 05:05 · Yahoo
Ginkgo Bioworks Q3 Earnings Call Highlights
2026-11-07 08:17 · Yahoo
Ginkgo Bioworks Holdings, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript
2026-11-06 07:47 · Yahoo
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
2026-11-05 21:05 · Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
2026-10-29 21:15 · Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-10-20 21:15 · Yahoo
Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand
2026-10-14 23:20 · Yahoo
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
2026-10-14 21:15 · Yahoo
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
2026-10-08 10:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.